Microbial Genomics as a Catalyst for Targeted Antivirulence Therapeutics

Frontiers in Medicine

Eby Sim¹  Nathan Bachmann²  Verlaine Timms²  Rebecca Rockett³  Matthew O'Sullivan⁴  Vitali Sintchenko⁴  Ben Marais⁵ 

[1] Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, Australia;Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, Australia;Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, Australia;Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, Australia;Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, Australia;Centre for Infectious Diseases and Microbiology—Public Health, Westmead Hospital, Westmead, NSW, Australia;Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology—Institute of Clinical Pathology and Medical Research, Westmead, NSW, Australia;Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Sydney, NSW, Australia;Children's Hospital at Westmead, Westmead, NSW, Australia;

关键词: virulence;    genome sequence analysis;    antibacterial treatment;    surveillance;    antimicrobial stewardship;   

DOI  :  10.3389/fmed.2021.641260

来源: Frontiers

【 摘 要 】

Virulence arresting drugs (VAD) are an expanding class of antimicrobial treatment that act to “disarm” rather than kill bacteria. Despite an increasing number of VAD being registered for clinical use, uptake is hampered by the lack of methods that can identify patients who are most likely to benefit from these new agents. The application of pathogen genomics can facilitate the rational utilization of advanced therapeutics for infectious diseases. The development of genomic assessment of VAD targets is essential to support the early stages of VAD diffusion into infectious disease management. Genomic identification and characterization of VAD targets in clinical isolates can augment antimicrobial stewardship and pharmacovigilance. Personalized genomics guided use of VAD will provide crucial policy guidance to regulating agencies, assist hospitals to optimize the use of these expensive medicines and create market opportunities for biotech companies and diagnostic laboratories.

【 授权许可】

CC BY